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describing their experience of a trans-
cranial Doppler system (Embo-Dop;
DWL Elektronische Systeme GmbH,
Singen, Germany) to discriminate be-
tween gaseous and particulate emboli
after aortic valve replacement. The
main finding of their study was that
solid microemboli occurred more fre-
quently after mechanical aortic valve
replacement compared with biological
valve replacement at 3 months after
surgery. The inability to distinguish
the difference between solid and gas-
eous microemboli has limited the use
of standard transcranial Doppler
when both coexist, for example, dur-
ing open carotid endarterectomy.
As the authors state, this particular
Doppler technique was first assessed
by Brucher and Russell2 in a 2-part
study comprising both in vitro and
in vivo models. The in vivo part
used 45 patients with carotid artery
stenosis (39 symptomatic), producing
a relatively low number of 32 em-
bolic signals, of which 30 were clas-
sified as solid.
The assumption in validation studies
is that all patients with carotid artery ste-
nosis produce only solid emboli. One
arm of a clinical validation study per-
formed by Markus and Punter3 used
a cohort of patients with symptomatic
carotid artery stenosis to generate 145
presumed solid embolic signals. Of
these145signals, theEmbo-Dopsystem
classified 72 as gaseous emboli. This
gavea sensitivity of 50.3% and specific-
ity of 96.5% for detecting solid embolic
signals. Markus and Punter concluded
that although the Embo-Dop system
allowed better discrimination than
simple intensity threshold alone, it
was not accurate enough for clinical
or research studies. Unless the specific-
ity is approximately 100%, a significant
number will be classified wrongly as
potentially significant solid emboli.
We believe that Embo-Dop has to be
used with caution in distinguishing gas-
eous from solid emboli.
The authors comment on no antipla-
telet therapy after mechanical versus
biological valve replacement. Our
group conducted a UK survey of con-
sultant practice and literature review of
this subject.4 We concluded that the
incidence of thromboembolism after
aortic bioprosthesis is highest in the
first 3 months but then diminishes.
Whether this is related to endotheli-
alization of prosthetic material or
specifically to antiplatelet therapy is
unknown. Therefore, their observation
that the proportion of particulate em-
boli at 3 months was in the biological
valve replacement cohort receiving as-
pirin but not in the mechanical group
receiving only warfarin could indeed
be explained by the antiplatelet func-
tion of aspirin.
Justin Nowell, MRCS
Marjan Jahangiri, FRCS (CTh)
St George’s Hospital
London, United Kingdom
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We thank Nowell and Jahangiri for
their interest in our recent article1 us-
ing a novel transcranial Doppler sys-
tem (Embo-Dop; DWL Elektronische
Systeme GmbH, Singen, Germany)
to investigate the number and nature
of cerebral microemboli in recipients
of biological and mechanical aortic
valve prostheses. The 2 important is-
sues highlighted by the authors in theird Cardiovascular Surgery c November 20Letter to the Editor were, in fact, both
discussed specifically in our article.
The first issue is the potentially low
sensitivity and specificity of the
Embo-Dop system as suggested in
the clinical validation study byMarkus
and Punter.2 With specific regard to
that study, we wrote in the discussion
section of our article: ‘‘More recently,
Markus and Punter, while confirming
the superior discrimination achievable
with this new Embo-Dop transcranial
Doppler system compared with
conventional transcranial Doppler
ultrasound, reported it to have a sensi-
tivity of only 50% but a specificity of
96% for detecting solid microemboli
in vivo. If confirmed, that finding
will only serve to emphasize the al-
ready significantly greater solid micro-
embolic load detected with mechanical
rather than biological prostheses.’’ In
other words, because the sensitivity
of the Embo-Dop system is much
lower than its specificity in detecting
solid microemboli, this will result in
an underestimation of the solid cere-
bral microembolic load.
The second issue raised by Nowell
and Jahangiri is that the reduction of
solid microemboli over time in the bi-
ological prosthesis recipients, but not
in the mechanical prosthesis recipi-
ents, could be explained by the use of
aspirin in the first group. Again, we
discussed that issue in our article stat-
ing, ‘‘Although biological recipients
were all receiving aspirin, mechanical
recipients received warfarin without
any antiplatelet agents. This could ex-
plain the reduction in the proportion of
particulate microemboli over time in
the biological valve group but not in
the mechanical group.’’ We subse-
quently suggested, ‘‘However, the re-
sults could also be affected by the
use of aspirin in the biologic valve
group, which would explain the reduc-
tion of microemboli detected over time
in group B (biological) but not in
group M (mechanical). Indeed, using
aspirin instead of warfarin after a
biological aortic valve implantation
is the current practice among the08
lation or act as a source of resistance to
the flow. The findings that none of their
patients had hepatomegaly or ascites on
physical examination and that the post-
operative echocardiograms showed ex-
cellent antegrade flow in the inferior
vena cava, which also was not dilated,
and minimal flow reversal in the hepatic
veins support the facilitation of smooth
forward flow. They presented a new op-
tion for constructing an extracardiac
Fontan connection with the Contegra
xenograft that has not been previously
published.Their earlyechocardiographic
results supported the idea of minimiz-
ing the reversal of infradiaphragmatic
venous flow, decreasing hepatic con-
gestion, and possibly reducing the de-
velopment of ascites.2 They do have
a way of assessing the conduit size by
using Rowlatt and colleagues’ chart.3
The authors routinely administered 5
mg/kg ticlopidine as antiplatelet ther-
than 10 kilograms. J Thorac Cardiovasc Surg.
2008;135:1145-52.
2. Baslaim G, Hussain A, Kouatli A, Jamjoom A. Bo-
vine valved xenograft conduits in the extracardiac
Fontan procedure. J Thorac Cardiovasc Surg.
2003;126:586-8.
3. Rowlatt JF, Rimaldi JMA, Lev M. The quantitative
anatomy of the normal child’s heart. Pediatr Clin
North Am. 1963;10:499-588.
4. Ovroutski S, Alexi-Meskishvili V. Does the Nakata
index predict outcome after Fontan operation? Eur
J Cardiothorac Surg. 2008;33:951.
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Reply to the Editor:
We appreciate Dr Sersar’s com-
ments on our recent article, ‘‘Feasibil-
ity of the Extracardiac Conduit Fontan
Procedure in Patients Weighing Less
than 10 Kilograms.’’ These comments
raise several questions concerning the
following: (1) choice of conduit type,
(2) anticoagulation therapy after the
Fontan procedure, and (3) examination
Letters to the Editormajority of cardiac surgeons, and con-
sequently our findings reflect a ‘real-
world’ situation.’’
Lorenzo Guerrieri Wolf, MD
Bikram P. Choudhary, MRCS
Yasir Abu-Omer, MRCS
David P. Taggart, MD (Hons), PhD,
FRCS
Department of Cardiothoracic Surgery
John Radcliffe Hospital
Oxford, United Kingdom
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To the Editor:
We read with the greatest interest
the article entitled ‘‘Feasibility of the
Extracardiac Conduit Fontan Proce-
dure in Patients Weighing Less than
10 Kilograms.’’1 After congratulating
the authors for their excellent work,
we have a few comments.
As a Fontan Conduit, they used poly-
tetrafluoroethylene (Gore-Tex; WL
Gore & Associates Inc, Flagstaff, Ariz)
(14–20 mm in diameter) King Faisal
Specialist Hospital and Research Center
in Jeddah, used Contegra valved con-
duits in 4 patients for inferior vena
cava–right pulmonary artery connection
(Fontan). They speculated that an
additional benefit of using the Contegra
xenograft couldbe that itprovidesacom-
petent valve in the Fontan circulation,
which might help by reducing the rever-
sal of flow and maintaining better
forward flow into the pulmonary
circulation. The concern was whether
the valve, in a nonpulsatile, passive Fon-
tan circulation, would facilitate smooth
antegradeflow into thepulmonary circu-
apy.Warfarinwas not used even though
they had a patient with arteriovenous
valve replacement. How did they con-
trol the thrombogenic potential here?
Measurement of the lower lobe in-
dex is an important adjunct to evaluate
candidates for the Fontan operation.
The predictive value of the Nakata in-
dex is less informative than the lower
lobe index, which was introduced to
optimize the preoperative selection of
Fontan candidates. Lower lobe index
may be more predictive to evaluate
the adequacy of the pulmonary vascu-
lar tree, given that central pulmonary
arteries used to calculate the Nakata in-
dex can be enlarged before or during
the Fontan operation.4
Sameh Ibrahim Sersar, MD
Ahmed A. Jamjoom, MD
Division of Cardiothoracic Surgery
Department of Cardiovascular
Diseases
King Faisal Specialist Hospital and
Research Center
Jeddah, Saudi Arabia
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In our article, we describe our strat-
egy for the extracardiac Fontan opera-
tion without fenestration. Our strategy
aimed to eliminate cyanosis as soon as
possible. Fenestration might reduce
the duration of pleural drainage but
cannot eliminate cyanosis even after
the Fontan procedure. We mentioned
in the article that peritoneal drainage
might be able to reduce the duration
of pleural drainage in small children
in particular. In addition to the obvious
purpose of the drainage of ascites it-
self, drainage of ascites also results in
the drainage of the inflammatory fac-
tors present in the ascites.1 In our se-
ries at least, there were no patients
with recurrent ascites after the cessa-
tion of the initial peritoneal drainage.
We have a chance to use a Contegra
conduit2 if this conduit is an attractive
option for reducing ascites and pleural
effusion. However, the use of this
conduit for the Fontan operation is
not permitted in Japan. The fate of
the conduit as a xenograft, especially
in terms of obstruction of conduit and
durability of valve function, over the
long term should be investigated.
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